within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07A_IntestinalAntiinfectives.A07AA03_Natamycin;

model Natamycin
  extends Pharmacolibrary.Drugs.ATC.A.A07AA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A07AA03</td></tr><td>route:</td><td>ocular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Natamycin is a polyene antifungal agent used primarily for topical treatment of fungal infections of the eye, such as fungal keratitis and conjunctivitis. It works by binding to ergosterol in fungal cell membranes, increasing membrane permeability, and leading to cell death. Natamycin is approved by regulatory agencies and is widely used today for ophthalmic infections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for natamycin are based on estimation, as published data for systemic pharmacokinetics is unavailable. Systemic absorption after ocular administration is minimal in healthy adults.</p><h4>References</h4><ol><li><p>Zhao, X, et al., &amp; Lu, H (2018). Comparison of the Ocular Penetration and Pharmacokinetics Between Natamycin and Voriconazole After Topical Instillation in Rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 34(6) 460–467. DOI:<a href=&quot;https://doi.org/10.1089/jop.2017.0139&quot;>10.1089/jop.2017.0139</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29792548/&quot;>https://pubmed.ncbi.nlm.nih.gov/29792548</a></p></li><li><p>Bhatta, RS, et al., &amp; Shukla, PK (2012). Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. <i>International journal of pharmaceutics</i> 432(1-2) 105–112. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2012.04.060&quot;>10.1016/j.ijpharm.2012.04.060</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22569234/&quot;>https://pubmed.ncbi.nlm.nih.gov/22569234</a></p></li><li><p>Datta, D, et al., &amp; Vora, LK (2024). Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics. <i>International journal of pharmaceutics</i> 658 124192–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2024.124192&quot;>10.1016/j.ijpharm.2024.124192</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38703931/&quot;>https://pubmed.ncbi.nlm.nih.gov/38703931</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Natamycin;
